Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)  is among the many 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of Barclays saved BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) at a Purchase ranking with a value goal of $86.00 in a report printed on June 10.

A pharmaceutical plant manufacturing a proprietary artificial oral type of a C-type natriuretic peptide.

In accordance with BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s most up-to-date earnings report, the agency made $745.15 million in income and $185.69 million in internet revenue for the quarter that ended on March 31. The corporate’s gross sales had been $648.83 million, and its internet revenue was $88.66 million final yr.

It’s difficult to keep away from previous comparisons with Genzyme (purchased by Sanofi) as BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) builds a portfolio of genetic-disease therapies. Regardless of having a number of licensed remedies, the agency spent years within the pink on account of commercialization and R&D prices, however analysts are optimistic concerning the long-term, worthwhile potential of its current portfolio. It’s in a powerful place due to its in depth inside pipeline and capability so as to add growth via strategic acquisitions.

Whereas we acknowledge the potential of BMRN as an funding, we consider sure AI shares supply higher upside potential and carry much less draw back danger. If you happen to’re in search of an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.